"/>

日本无限资源_福禄影院午夜伦_美国av毛片_亚洲自拍在线观看_激情亚洲一区国产精品_999久久久久

FDA approves new drug for patients with multi-drug-resistant HIV

Source: Xinhua    2018-03-07 06:07:40

WASHINGTON, March 6 (Xinhua) -- The United States Food and Drug Administration (FDA) approved on Tuesday a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other currently available therapies.

Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

"Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options. New treatment options may be able to improve their outcomes," said Jeff Murray, deputy director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research.

While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug resistant HIV, limiting their treatment options and putting them at a high risk of HIV-related complications and progression to death, according to FDA.

The safety and efficacy of Trogarzo were evaluated in a clinical trial of 40 heavily treatment-experienced patients with multi-drug resistant HIV-1 who continued to have high levels of virus (HIV-RNA) in their blood despite being on antiretroviral drugs. Many of the participants had previously been treated with 10 or more antiretroviral drugs.

The majority of participants experienced a significant decrease in their HIV-RNA levels one week after Trogarzo was added to their failing antiretroviral regimens.

After 24 weeks of Trogarzo plus other antiretroviral drugs, 43 percent of the trial's participants achieved HIV RNA suppression, FDA said.

A total of 292 patients with HIV-1 infection have been exposed to Trogarzo IV infusion. The most common adverse reactions to Trogarzo were diarrhea, dizziness, nausea and rash. Severe side effects included rash and changes in the immune system.

Editor: Liu
Related News
Xinhuanet

FDA approves new drug for patients with multi-drug-resistant HIV

Source: Xinhua 2018-03-07 06:07:40

WASHINGTON, March 6 (Xinhua) -- The United States Food and Drug Administration (FDA) approved on Tuesday a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other currently available therapies.

Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

"Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options. New treatment options may be able to improve their outcomes," said Jeff Murray, deputy director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research.

While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug resistant HIV, limiting their treatment options and putting them at a high risk of HIV-related complications and progression to death, according to FDA.

The safety and efficacy of Trogarzo were evaluated in a clinical trial of 40 heavily treatment-experienced patients with multi-drug resistant HIV-1 who continued to have high levels of virus (HIV-RNA) in their blood despite being on antiretroviral drugs. Many of the participants had previously been treated with 10 or more antiretroviral drugs.

The majority of participants experienced a significant decrease in their HIV-RNA levels one week after Trogarzo was added to their failing antiretroviral regimens.

After 24 weeks of Trogarzo plus other antiretroviral drugs, 43 percent of the trial's participants achieved HIV RNA suppression, FDA said.

A total of 292 patients with HIV-1 infection have been exposed to Trogarzo IV infusion. The most common adverse reactions to Trogarzo were diarrhea, dizziness, nausea and rash. Severe side effects included rash and changes in the immune system.

[Editor: huaxia]
010020070750000000000000011100851370207631
主站蜘蛛池模板: 精品人伦一区二区三区蜜桃免费 | 激情综合色五月丁香六月亚洲 | 免费中午字幕无吗 | 免费无码专区在线视频 | 国产精品-去看片 | 国产精品区一区二区三在线播放 | 在线看片福利 | 亚洲宅男网av| 免费的黄 | 国产成人亚洲综合a∨婷婷图片 | 国产亚洲日韩欧美另类第八页 | 欧美俄罗斯40老熟妇 | 久久丫精品国产免费 | 亚洲AV日韩AV在线观看 | 亚洲AV丝袜美腿无码播放器 | 91精品视频免费在线观看 | 国产三级在线观看播放 | 久一在线视频 | 91精品久久久久五月天精品 | 天天操天天射综合网 | 好硬啊进得太深了A片无码公司 | 国产成人精品久久亚洲高清不卡 | 久久亚洲综合色 | 日韩人妻无码中文字幕视频 | 囯产黄色视频一级黄片 | 久久久精品久久日韩一区综合 | 亚洲av日韩av成人av | 真人作爱免费视频 | 日韩午夜在线观看 | 免费在线观看视频完整 | 欧美性受xxxx白人性爽 | 九一视频免费在线观看 | 亚洲av人人夜夜澡人人 | 一区二区久久久久草草 | 四虎影视久久久免费 | 国产日产欧洲无码视频无遮挡 | 男人狂桶女人出白浆免费视频 | 免费可以看的无遮挡AV | 亚洲色无色A片一区二区农夫 | 在线观看一区 | 91福利精品第一导航禁漫天堂 |